Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is currently conducting a Phase 3 clinical study titled ‘AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE.’ The study aims to evaluate the safety and effectiveness of rimegepant, a dissolvable tablet, in preventing migraines in adolescents who experience frequent migraine attacks.
The intervention being tested is rimegepant, an orally disintegrating tablet designed to prevent migraines. Participants will receive either rimegepant or a placebo to assess the drug’s efficacy and safety.
This study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. It involves quadruple masking to ensure unbiased results, focusing primarily on migraine prevention.
The study began on November 15, 2024, with an estimated completion date yet to be announced. The latest update was submitted on July 8, 2025, indicating ongoing recruitment and progress.
This clinical update could positively impact Pfizer’s stock performance by demonstrating innovation in migraine treatment, potentially boosting investor confidence. Competitors in the migraine treatment market may also feel pressure to advance their research and development efforts.
The study is ongoing, with further details available on the ClinicalTrials portal.